Benign Conditions

“As part of the [MAPP] network, and the research that it did, we recognized that it was really important to consider pelvic pain symptoms separately from urinary symptoms,” says Alisa J. Stephens-Shields, PhD.

"It may be something that practicing urologists could already start speaking to their patients about," says Siobhan Sutcliffe, PhD, ScM, MHS.

"We used data from this study to see whether having a greater number of flares independently impacted patients’ quality of life as well as their healthcare seeking activity," said Siobhan Sutcliffe, PhD, ScM, MHS.

The study authors maintain there is no current evidence in the literature indicating that CT use is superior to other imaging modalities in reducing morbidity or improving outcomes in patients with urinary stone disease.

The researchers assessed gender differences in patients with interstitial cystitis/bladder pain syndrome (IC/BPS).

“We observed profound differences in the detection work up and management of chronic kidney disease suggesting suboptimal care among women,” said Juan Jesus Carrero, PharmD, PhD.

"As we look back over the past 5 decades in urology, bladder dysfunction, particularly inadequate contraction, is still a disorder with unmet medical need, for which new treatments are crucial," writes Gopal H. Badlani, MD.

Fluoroquinolone could increase the risk of altered mental status and hospitalizations for older patients with advanced chronic kidney disease.

Addressing the gaps in health literacy may lead to improvement in health outcomes and health care disparities among patients with chronic pelvic pain.

Elisabeth M. Sebesta, MD, coauthor of a recent study, reported that patients who experienced more unmet social needs were at increased risk of multiple urologic conditions, such as overactive bladder, interstitial cystitis, or urge incontinence.

In this interview, Andrea Staack, MD, PhD, discusses the background, findings, and takeaways of the study, "Mindfulness based-stress reduction is associated with decreased levels of patients’ anxiety after urodynamics- A prospective randomized controlled trial," along with why urologists should consider implementing more strategies of this effect in their practices.

“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.

In this interview, Ashley Winter, MD, discusses why urologists should play a role in the management of STDs and STIs, especially when it comes to destigmatizing them.

“I think people can feel like they're all alone, or they have something that's uncommon, and it may not be,” says J. Quentin Clemens, MD, FACS, MSCI.

"Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.

“Optilume exhibited a significant improvement in [the primary] objective outcome at 6 months and subjective outcomes at 1-year post treatment compared to standard of care,” said Justin Chee, MBBS, FRACS.

In the pivotal phase 3 DAPA-CKD trial, dapagliflozin reduced the relative risk of worsening of renal function, onset of end-stage kidney disease, or cardiovascular or renal death by 39%.

The FDA’s decision not to approve roxadustat follows a vote from the agency’s Cardiovascular and Renal Drugs Advisory Committee that the drug’s benefit-risk profile does not support approval.

The FDA has issued a complete response letter regarding a new drug application for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

The mechanism of action of roxadustat differs from that of erythropoietin stimulating agents.

Lumasiran is the first drug approved by the FDA for the treatment of patients with primary hyperoxaluria type 1.

The application for the targeted release formulation of budesonide is supported by data from the phase 3 NefIgArd trial and the phase 2 NEFIGAN trial.

The retrospective study compared reintervention rates in the 4 standard surgical interventions for lower urinary tract symptoms due to benign prostatic obstruction.

Minimally-invasive treatment with the iTind device (Medi-Tate) provides rapid and sustained improvement of LUTS in men with BPH, without adversely affecting patients’ sexual function, according to a recently published 12-month study.

Lobe enucleation efficiency is significantly better with Moses technology, investigators report.